Literature DB >> 16338274

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.

R Scott Obach1, Robert L Walsky, Karthik Venkatakrishnan, J Brian Houston, Larry M Tremaine.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16338274     DOI： 10.1016/j.clpt.2005.09.004

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  27 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Authors:  Daniel R McMasters; Rhonda A Torres; Susan J Crathern; Deborah L Dooney; Robert B Nachbar; Robert P Sheridan; Kenneth R Korzekwa
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

4.  Correction to "Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213".

Authors:  Ilia G Denisov; Yelena V Grinkova; Prithviraj Nandigrami; Mrinal Shekhar; Emad Tajkhorshid; Stephen G Sligar
Journal:  Biochemistry       Date:  2019-06-06       Impact factor: 3.162

5.  Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.

Authors:  Garrett R Ainslie; Kristina K Wolf; Yingxin Li; Elizabeth A Connolly; Yolanda V Scarlett; J Heyward Hull; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2014-09-24       Impact factor: 4.030

6.  Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.

Authors:  Erik Mogalian; Polina German; Brian P Kearney; Cheng Yong Yang; Diana Brainard; John McNally; Lisa Moorehead; Anita Mathias
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

7.  Drug Distribution. Part 1. Models to Predict Membrane Partitioning.

Authors:  Swati Nagar; Ken Korzekwa
Journal:  Pharm Res       Date:  2016-12-15       Impact factor: 4.200

8.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Authors:  Cong Xu; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2013-02-05       Impact factor: 3.614

Review 9.  Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Pharmacol Ther       Date:  2012-08-04       Impact factor: 12.310

10.  Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results.

Authors:  M J Hanley; G Masse; J S Harmatz; M H Court; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.